glioblastoma multiformeDIAGNOSISTREATMENTpatterns of invasioninvasion mechanismGlioblastoma multiforme(GBM) is an essentially incurable brain tumor, which has been explored for approximately a century. Nowadays, surgical resection, chemotherapy, and radiation therapy are still the standardized therapeutic options....
The AlgTubes will also significantly advance the precision or personalized medicine. There are large variations between tumors or patients in terms of the genetics, epigenetics, cellular compositions and drug response or resistance53. The conventional method of using one treatment or drug (e.g. chemo...
BACKGROUNDSocial factors influence cancer treatment choices, potentially affecting patient survival. In the current study, the authors studied the interrelations between marital status, treatment received, and survival in patients with glioblastoma multiforme (GM), using population-based data.METHODSThe data...
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with an extremely low survival rate. New and effective approaches for treatment are therefore urgently needed. Here, we successfully developed M1-like macrophage-derived extracellular vesicles (M1EVs) that overcome multiple challenges via g...
GBM: Glioblastoma multiforme CRM1: Chromosome region 1 NES: Nuclear export signal CCK-8: Cell counting kit-8 EdU: 5-ethynyl-2′-deoxyuridine DAPI: 4′,6-diamidino-2-phenylindole References Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG, Quinones-Hinojosa...
Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings. Eur Radiol. 2017;27(10):4188–97. Article PubMed Google Scholar An Z, Aksoy O, Zheng T, Fan QW, ...
at Lerner Research Institute, Cleveland Clinic reported in the November 8, 2021, issue ofNatureCancerthat an inhibitor of the beta-amyloid producing enzyme, BACE1, could reprogram tumor-promoting M2 macrophages to exert M1 tumor-suppressing activities in animal models of glioblastoma multiforme (GBM)...
Background: Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma. TMZ has widely replaced the procarbazine, lomustine plus vincristine (PCV) combination for the treatment of malignant brain tumours as a result...
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical ...
The current standard of treatment for glioblastoma is the combination of maximal safe resection, radiation, and chemotherapy; this paradigm was shown to prolong the median overall survival to 14.6 months1,2. Immunotherapeutic agents, which utilize the body’s innate immune responses to kill cancerous...